OncoNano Medicine
Matthew Head is the CFO of OncoNano, joining the company in March 2018. He has over 25 years experience in the pharmaceutical industry. Prior to OncoNano, Matthew was the VP, Head of Finance at ZS Pharma, Inc., which was acquired by AstraZeneca in 2015 for $2.7 billion. Previously, Matthew was the Head of Finance for the US Pharmaceuticals and Consumer Products divisions at Alcon. With Alcon for 17 years, Matthew also has experience in US/global treasury, investor relations, operational finance, product launches, strategic planning, M&A and global communications. Mr. Head holds an MBA from the Neeley School of Business at Texas Christian University and a BA in economics from The University of the South.
This person is not in any offices
OncoNano Medicine
OncoNano Medicine is developing a new class of pH-activated compounds that digitalize and exploit the variability of pH in disease. pH variability is a proven, simple, and effective identifier of diseased tissue providing a foundation for the development of a broad range of highly targeted therapeutics and imaging agents.